Kala Bio shares surged 63% premarket to 48 cents after announcing the launch of its first purpose-built AI agent for biotech in just 14 days through the rebranded Researgency.ai platform.
KALA BIO secures $6M investment from David E. Lazar, names him CEO and Chairman, and plans to continue developing eye disease therapies after CHASE trial setbacks.
KALA BIO’s lead drug, KPI-012, failed its Phase 2b trial for Persistent Corneal Epithelial Defect (PCED), prompting the company to stop development and pursue cash-saving strategic options.
